Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Sofosbuvir for the treatment of patients with genotype 4 hepatitis C: a review of the clinical efficacy, cost-effectiveness, and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions Sofosbuvir in combination with peginterferon and ribavirin is recommended for treatment of naïve-patients, who are eligible and not eligible to receive interferon, as well as those who are peginterferon/ribavirin non-responders. There was no evidence of comparative clinical efficacy and cost-effectiveness of sofosbuvir for the treatment of HCV genotype 4 identified. Indexing Status Subject indexing assigned by CRD MeSH Genotype; Hepacivirus; Hepatitis Cs Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32016000175 Date abstract record published 28/01/2016 |